BR0314006A - Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêutica - Google Patents
Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêuticaInfo
- Publication number
- BR0314006A BR0314006A BR0314006-7A BR0314006A BR0314006A BR 0314006 A BR0314006 A BR 0314006A BR 0314006 A BR0314006 A BR 0314006A BR 0314006 A BR0314006 A BR 0314006A
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- disease
- group
- disease selected
- lupus
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 208000037147 Hypercalcaemia Diseases 0.000 title abstract 3
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 230000000148 hypercalcaemia Effects 0.000 title abstract 3
- 208000030915 hypercalcemia disease Diseases 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 2
- 208000032839 leukemia Diseases 0.000 title abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 210000000056 organ Anatomy 0.000 title abstract 2
- 231100000816 toxic dose Toxicity 0.000 title abstract 2
- 229930003231 vitamin Natural products 0.000 title abstract 2
- 229940088594 vitamin Drugs 0.000 title abstract 2
- 235000013343 vitamin Nutrition 0.000 title abstract 2
- 239000011782 vitamin Substances 0.000 title abstract 2
- -1 vitamin compound Chemical class 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 206010052779 Transplant rejections Diseases 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 7
- 201000011510 cancer Diseases 0.000 abstract 7
- 210000000988 bone and bone Anatomy 0.000 abstract 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 4
- 229910052791 calcium Inorganic materials 0.000 abstract 4
- 239000011575 calcium Substances 0.000 abstract 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 abstract 2
- 229930003316 Vitamin D Natural products 0.000 abstract 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 2
- 230000002308 calcification Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 235000019166 vitamin D Nutrition 0.000 abstract 2
- 239000011710 vitamin D Substances 0.000 abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 2
- 229940046008 vitamin d Drugs 0.000 abstract 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 229940062527 alendronate Drugs 0.000 abstract 1
- 210000000709 aorta Anatomy 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/235,244 US7259143B2 (en) | 2002-09-05 | 2002-09-05 | Method of extending the dose range of vitamin D compounds |
| PCT/US2003/020517 WO2004022068A1 (en) | 2002-09-05 | 2003-06-26 | A method of extending the dose range of vitamin d compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0314006A true BR0314006A (pt) | 2005-08-09 |
Family
ID=31977538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314006-7A BR0314006A (pt) | 2002-09-05 | 2003-06-26 | Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7259143B2 (https=) |
| EP (1) | EP1545549A1 (https=) |
| JP (1) | JP2006500388A (https=) |
| KR (1) | KR100835456B1 (https=) |
| CN (1) | CN1694711A (https=) |
| AU (2) | AU2003245748A1 (https=) |
| BR (1) | BR0314006A (https=) |
| CA (1) | CA2497828A1 (https=) |
| MX (1) | MXPA05002467A (https=) |
| NZ (1) | NZ539129A (https=) |
| PL (1) | PL375558A1 (https=) |
| WO (1) | WO2004022068A1 (https=) |
| ZA (1) | ZA200501843B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
| CA2480814A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US7566696B2 (en) * | 2002-09-05 | 2009-07-28 | Wisconsin Alumni Research Foundation | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| AU2004266706B2 (en) * | 2003-08-20 | 2009-07-30 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-vitamin D2 compounds |
| WO2005027929A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen |
| CA2539361A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| US7704980B2 (en) * | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
| WO2006061683A1 (en) * | 2004-12-09 | 2006-06-15 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta |
| WO2006086661A2 (en) * | 2005-02-10 | 2006-08-17 | Above Sea Level, Llc | Lead generation method and system |
| AU2006213727B2 (en) * | 2005-02-11 | 2011-08-18 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2 |
| NZ561076A (en) * | 2005-02-11 | 2010-01-29 | Wisconsin Alumni Res Found | 2-methylene-19-nor-(20S-24EPI)-1alpha,25-dihydroxyvitamin-D2 |
| WO2006088765A1 (en) * | 2005-02-14 | 2006-08-24 | Wisconsin Alumni Research Foundation | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| KR20080050420A (ko) * | 2005-08-18 | 2008-06-05 | 비옥셀 에스.피.에이. | 1α-플루오로-25-히드록시-16-23Ｅ-디엔-26,27-비스호모-20-에피-콜레칼시페롤의 합성 |
| US20070165866A1 (en) * | 2006-01-13 | 2007-07-19 | Motorola, Inc. | Method and apparatus to facilitate conveying audio content |
| KR20190028822A (ko) * | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| US20100331286A1 (en) * | 2008-02-25 | 2010-12-30 | Ray Chow | Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function |
| TR200900880A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik bileşimler. |
| TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
| CA2776464C (en) * | 2009-10-02 | 2017-10-24 | Wisconsin Alumni Research Foundation | 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses |
| WO2012075326A2 (en) * | 2010-12-01 | 2012-06-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of inflammatory diseases by targeting the adaptor protein ciks |
| US8410080B1 (en) * | 2011-10-21 | 2013-04-02 | Wisconsin Alumni Research Foundation | 2-methylene-vitamin D analogs and their uses |
| JP6971966B2 (ja) * | 2015-08-05 | 2021-11-24 | ウイスコンシン アラムニ リサーチ ファンデーション | カルシトリオールの２−メチレン類似体および関連化合物の合成および生物活性 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6357527A (ja) | 1986-08-28 | 1988-03-12 | Toyo Jozo Co Ltd | 薬剤の吸着防止方法 |
| US5391567A (en) * | 1986-09-03 | 1995-02-21 | Macrochem Corporation | Method for treating hypercalcemia using salts of TNCA |
| US6489288B1 (en) * | 1990-03-16 | 2002-12-03 | Applied Research Systems Ars Holding | Treatment of polycystic ovarian disease |
| US5780437A (en) * | 1995-12-14 | 1998-07-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6503893B2 (en) * | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6034075A (en) * | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
| WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| EP1267888A4 (en) * | 2000-01-04 | 2005-12-28 | Univ California | USE OF LOW DOSE BISPHOSPHONATES TO INHIBIT CARDIAC AND ARTERIAL CALCIFICATION |
| EP1416919A1 (en) * | 2001-07-17 | 2004-05-12 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
-
2002
- 2002-09-05 US US10/235,244 patent/US7259143B2/en not_active Expired - Fee Related
-
2003
- 2003-06-26 EP EP03739354A patent/EP1545549A1/en not_active Withdrawn
- 2003-06-26 MX MXPA05002467A patent/MXPA05002467A/es active IP Right Grant
- 2003-06-26 PL PL03375558A patent/PL375558A1/xx not_active Application Discontinuation
- 2003-06-26 JP JP2004534233A patent/JP2006500388A/ja active Pending
- 2003-06-26 CN CNA038248883A patent/CN1694711A/zh active Pending
- 2003-06-26 AU AU2003245748A patent/AU2003245748A1/en not_active Abandoned
- 2003-06-26 NZ NZ539129A patent/NZ539129A/en not_active IP Right Cessation
- 2003-06-26 KR KR1020057003765A patent/KR100835456B1/ko not_active Expired - Fee Related
- 2003-06-26 WO PCT/US2003/020517 patent/WO2004022068A1/en not_active Ceased
- 2003-06-26 BR BR0314006-7A patent/BR0314006A/pt not_active IP Right Cessation
- 2003-06-26 CA CA002497828A patent/CA2497828A1/en not_active Abandoned
-
2005
- 2005-03-03 ZA ZA200501843A patent/ZA200501843B/en unknown
-
2009
- 2009-09-21 AU AU2009217403A patent/AU2009217403A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ539129A (en) | 2008-05-30 |
| CN1694711A (zh) | 2005-11-09 |
| KR20050057180A (ko) | 2005-06-16 |
| ZA200501843B (en) | 2006-05-31 |
| WO2004022068A1 (en) | 2004-03-18 |
| US7259143B2 (en) | 2007-08-21 |
| PL375558A1 (en) | 2005-11-28 |
| MXPA05002467A (es) | 2005-05-27 |
| CA2497828A1 (en) | 2004-03-18 |
| KR100835456B1 (ko) | 2008-06-09 |
| US20040053813A1 (en) | 2004-03-18 |
| EP1545549A1 (en) | 2005-06-29 |
| JP2006500388A (ja) | 2006-01-05 |
| AU2003245748A1 (en) | 2004-03-29 |
| AU2009217403A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0314006A (pt) | Métodos de administração de dose tóxica de um composto de vitamina d a um mamìfero, sem desenvolvimento de hipercalcemia, e de tratemento da psorìase, de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer da mama ou câncer de próstata, de doença auto-imune selecionada do grupo que consiste em esclerose múltipla, lúpus, doença inflamatória do intestino, diabete do tipo i, reação do hospedeiro contra enxerto e rejeição de transplante de órgão e composição farmacêutica | |
| JP4493340B2 (ja) | １α−ヒドロキシ−２−メチレン−１９−ノル−プレグナカルシフェロール及びその使用 | |
| Brown et al. | New active analogues of vitamin D with low calcemic activity. | |
| US20040033998A1 (en) | (20S)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses | |
| BR0309405A (pt) | Compostos e métodos de tratamento da psorìase de doença selecionada do grupo que consiste em leucemia, câncer de cólon, câncer de peito ou câncer de próstata, de doença autoimune, de doença inflamatória, de condição de pele e de doença metabólica do osso | |
| IL153908A (en) | Pharmaceutical preparations containing 2α - methyl - 19 - nur - (S) 20 - 1α, 25 - dihydroxyvitamin D3 | |
| JP2007505886A (ja) | ２−メチレン−１９−ノル−ビタミンｄ誘導体及びビスホスフォネートの組み合わせを含む医薬組成物及び方法 | |
| JP2004505022A (ja) | 骨強度を増加するための２−メチレン−１９−ノル−２０（Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 | |
| Norman | The vitamin D endocrine system: Manipulation of structure‐function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents | |
| ATE537834T1 (de) | 2-methylen-19-nor-vitamin d2-verbindungen | |
| Foegh et al. | Early inhibition of myointimal proliferation by angiopeptin after balloon catheter injury in the rabbit | |
| KR100983953B1 (ko) | 신생 골의 형성을 유도하기 위한 탄소-2-개질된 19-노르-비타민 ｄ 유사체의 용도 | |
| Sava et al. | Mechanism of the Antimetastatic Action of Dimethyltriazenes 1, 2 | |
| AU2004273660B2 (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone | |
| BRPI0409194A (pt) | compostos, composição farmacêutica e método de tratamento de doença metabólica do osso, da psorìase, da leucemia, cáncer do cólon, cáncer da mama, cáncer da pele ou cáncer da próstata, de doença auto-imune, de doença inflamatória do intestino e de aumento da resistência do osso | |
| RU2057117C1 (ru) | ГОМОЛОГИ 1α - ГИДРОКСИВИТАМИНА D3 С НЕНАСЫЩЕННОЙ БОКОВОЙ ЦЕПЬЮ, КОМПОЗИЦИЯ, СПОСОБСТВУЮЩАЯ СТИМУЛЯЦИИ И УСИЛЕНИЮ ДИФФЕРЕНЦИАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ЛЕЙКЕМИИ ЧЕЛОВЕКА, СПОСОБ СТИМУЛЯЦИИ И УСИЛЕНИЯ ДИФФЕРЕНЦИАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ЛЕЙКЕМИИ ЧЕЛОВЕКА | |
| JP2007523162A (ja) | ２‐メチレン‐１９‐ノル‐２０（Ｓ）‐１α，２５‐ジヒドロキシビタミンＤ３の骨疾患の予防のための使用 | |
| Milne et al. | Vitamin D handbook: structures, synonyms, and properties | |
| Seiichi et al. | The difference of biological activity among four diastereoisomers of 1α, 25-dihydroxycholecalciferol-26, 23-lactone | |
| Reeve et al. | Biological activity of 1 α-hydroxyvitamin D2 in the rat | |
| US4428946A (en) | Method of preventing milk fever in dairy cattle | |
| Jacobsson et al. | Distribution of selenium in mice studied by whole-body autoradiography after injection of Se75-sodium selenite | |
| Procsal et al. | Studies on the mode of action of calciferol: Biological activity of 1α, 24R, 25-trihydroxyvitamin D3 in the chick | |
| Wigington et al. | Pamidronate and 1, 24 (S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells | |
| Haddad Jr et al. | Phosphorus deprivation: the metabolism of vitamin D3 and 25-hydroxycholecalciferol in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CI. A61K 31/59, A61P 35/00, A61P 17/00 Ipc: A61K 31/59 (2011.01), A61P 35/00 (2011.01), A61P 1 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |